What Is KLOW? Four Ingredients, KPV and the Evidence

Apex Laboratory / KLOW explained

The useful question is not simply whether KLOW has “more peptides.” It is what the fourth ingredient changes, which studies actually tested it, and what a record can tell you about the material. Start with the formula, then follow KPV’s evidence without confusing an added ingredient with an established added benefit.

KLOW versus GLOW: one ingredient changes

For these two Apex configurations, KPV is the only added component. The 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500 are the same in both formulas. “80 mg” is the sum of four labeled amounts; it does not mean that each ingredient increased or that a solution is more concentrated.

The added-component ledger

Three unchanged amounts. One addition.

Component	GLOW70 mg total	KLOW80 mg total
GHK-Cu	50 mg	50 mg
BPC-157	10 mg	10 mg
TB-500 fragment	10 mg	10 mg
KPV	Not included	10 mg

Combined labeled mass70 mg → 80 mg

The GLOW guide explains the shared three-component formula. For a broader comparison that also includes the two-component BPC-157/TB-500 blend, see KLOW, GLOW and BPC/TB-500 compared.

What does KPV mean?

That identity also differs from the TB-500 fragment in this blend. Apex identifies TB-500 as Ac-LKKTETQ, an acetylated seven-residue sequence, rather than the full-length 43-residue thymosin beta-4 protein. The 2012 analytical identification supports that distinction. Neither fragment should inherit every finding reported for its parent molecule.

What do the claimed KLOW benefits rest on?

The ingredient studies do not establish a benefit for the complete KLOW formula. KPV has been studied in cell and mouse systems, including inflammatory-signaling models. Those findings explain why it attracts research interest. They do not show what adding KPV to GHK-Cu, BPC-157 and TB-500 does in one vial, or establish an effect in people.

Two different questions

Does this formula include another ingredient?

Yes. The two declared configurations answer that directly: KLOW includes KPV 10 mg.

Does the extra ingredient produce an extra effect?

That needs evidence comparing the relevant materials under defined conditions. A label, a plausible mechanism and a study of KPV alone cannot answer it.

Study detail: why a simple KPV receptor label is misleading

Getting and colleagues reported reduced inflammatory-cell migration in a mouse model even when MC1R was nonfunctional. KPV did not inhibit two measured macrophage cytokine responses in that same paper. Kannengiesser and colleagues later described activity as at least partly independent of MC1R in mouse colitis models. These are specific observations, not a universal receptor rule. Getting 2003; Kannengiesser 2008.

A 2003 review described KPV binding to MC1R, while a 2010 review said it lacks the motif required for binding known melanocortin receptors and that its precise signaling mechanism was unknown. The author groups overlap, so these are not two independent laboratories establishing opposing mechanisms. Luger 2003; Brzoska 2010.

Land’s study proposed an importin-α/p65 mechanism in a bronchial cell line. Broader reviews discuss related alpha-MSH peptides, but do not turn those models into a demonstrated KLOW mechanism or human result. Land 2012; Luger and Brzoska 2007; Brzoska and colleagues 2008.

Study detail: chemical form and delivery system matter

Cutuli and colleagues reported antimicrobial observations, but their abstract does not identify KPV’s terminal form. Songok and colleagues found no antimicrobial activity for the modified form Ac-KPV-NH₂. Those descriptions are not interchangeable with an unmodified free-acid KPV record. Cutuli 2000; Songok 2018.

Xiao and colleagues studied KPV in hyaluronic-acid-functionalized nanoparticles and a chitosan/alginate hydrogel. A delivery system can change the experiment; it is not equivalent to KPV as one ingredient in a lyophilized four-component blend. Xiao 2017. The dedicated KPV guide follows the identity and study details.

The other three ingredients keep their own evidence

GHK-Cu, BPC-157 and TB-500 do not become a single molecule when their names appear together. GHK-Cu is the copper complex, not free GHK. BPC-157 is a 15-residue peptide. TB-500 here is the acetylated seven-residue fragment. Each needs its own material identity and its own interpretation.

GHK-Cu: a culture finding is not a blend outcome

Maquart and colleagues reported increased collagen synthesis in fibroblast cultures. That is a defined cell-system observation. Reviews by Pickart and colleagues explore GHK-related biology, but their publication count cannot be treated as independent replication of a four-ingredient mixture. Maquart 1988; Pickart 2008; Pickart and colleagues 2015. See the GHK-Cu guide for the wider evidence.

BPC-157: distinguish individual experiments from reviews

Hsieh and colleagues examined vascular-cell and animal models, reporting VEGFR2-associated signaling and vascular responses. The reviews by Sikiric and Seiwerth summarize a broader preclinical program; they are not separate clinical demonstrations of KLOW. Hsieh 2017; Sikiric 2016; Seiwerth 2018. The BPC-157 guide separately examines its human reports and registered studies.

TB-500: the parent, fragment and metabolites are different test materials

Philp’s 2003 study investigated a short actin-binding motif in migration and sprouting assays. That motif evidence should not erase the terminal-chemistry distinction between LKKTETQ and acetylated Ac-LKKTETQ. Philp 2003.

A 2024 study compared acetylated TB-500 with metabolites in a fibroblast assay. Only the metabolite Ac-LKKTE showed significant scratch-closure activity relative to control. The result belongs to that molecule and assay, not to the intact fragment, people or KLOW. Rahaman 2024. The TB-500 guide explains the fragment-versus-parent relationship.

Has the complete KLOW blend been studied?

In the scoped PubMed and ClinicalTrials.gov searches checked on September 8, 2026, no study of the exact GHK-Cu/BPC-157/TB-500/KPV 50/10/10/10 formula was identified. Searches by the word “KLOW” produced unrelated records, so a name match alone was not counted as blend evidence. This is a dated search finding, not a claim to have found every unpublished experiment.

The closest cited combination experiment studied BPC-157, material named TB-500, and the two together in 32 rats after Achilles-tendon injury. It included neither GHK-Cu nor KPV. The combined arm did not provide an additional benefit over either single-component arm; its total Movin score was lower than control, but only the TB-500 arm reached significance on the maximum-load outcome. The paper did not specify the TB material’s sequence or mass. It therefore cannot establish a KLOW effect or equivalence to Apex’s fragment. Biçer and colleagues, 2026.

For someone comparing claimed benefits, that leaves a practical distinction: a rationale for investigating ingredients is available; a demonstrated result for this exact four-component preparation is not established by these records.

Read a KLOW report without mixing up its numbers

The label, a content assay and a chromatographic result answer different questions. This example uses the published Apex Laboratory report for one identified configuration and lot. It shows how to read the fields, not which lot an order will receive.

On a narrow screen, scroll the result table horizontally to read every column.

Source: view report APX-COA-2026-0806-K. These are the report’s stated, component-specific results. The active-content column uses mg/vial; the purity column uses integrated detector area under an analyte-specific method. Neither averaging the four percentages nor multiplying a label amount by an area percentage produces a valid combined-content result.

The issue date identifies the certificate; it is not a testing date. An in-house report is not independent third-party analysis, and the public record does not identify the lot currently shipping. Read any other endpoint under its own stated method and sampling scope. None of these analytical measurements demonstrates a four-component clinical effect.

For help with the fields, use the COA-reading guide, HPLC result guide and mass-spectrometry identity guide. The Lab Verified library lists published records. Current material options belong on the KLOW product page.

Frequently Asked Questions about KLOW

Is KLOW one peptide or four?

KLOW is a blend of four materials, not a single peptide. Apex’s 80 mg configuration is labeled GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Each component retains its own molecular identity and evidence.

What is the difference between KLOW and GLOW?

For these Apex configurations, both formulas have the same labeled GHK-Cu, BPC-157 and TB-500 amounts. KLOW adds KPV 10 mg, increasing the total from 70 to 80 mg. That difference does not establish a stronger or better effect.

What does KPV stand for?

KPV represents lysine, proline and valine. It is a three-amino-acid sequence corresponding to the C-terminal segment of alpha-MSH. That relationship does not establish that KPV behaves like the complete hormone or binds the same receptors.

Does 80 mg mean KLOW is more concentrated?

No. The 80 mg figure is the total labeled mass of the four components. A solution concentration also requires a volume and a specified component or total basis. The label alone does not provide that information.

Has the complete KLOW blend been studied?

The scoped PubMed and ClinicalTrials.gov searches checked on September 8, 2026 did not identify a study of the exact 50/10/10/10 formula. Component studies and partial combinations do not establish a result for the complete four-component preparation.

Do KPV studies show that KLOW works better than GLOW?

No. Studies of KPV in a defined cell or mouse model do not establish the effect of adding it to the other three ingredients. A comparison of the relevant complete preparations would be needed to assess an incremental effect.

What are the side effects of KLOW?

These records do not establish the human safety profile of the exact blend. Findings about an individual component, chemical form or animal model cannot reliably quantify the risks of the four-component preparation in people. A laboratory COA does not resolve that gap.

Does a KLOW COA prove a biological effect?

No. The certificate reports specified results for a named configuration and lot. Component identity, chromatographic detector area and active content answer separate analytical questions. They do not establish a combined clinical effect. Its issue date is also distinct from a testing date.

Sources and study details

1. Philp D et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003. PMID 14500546.
2. Cutuli M et al. Antimicrobial effects of alpha-MSH peptides. Journal of leukocyte biology. 2000. PMID 10670585.
3. Getting SJ et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. The Journal of pharmacology and experimental therapeutics. 2003. PMID 12750433.
4. Luger TA et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences. 2003. PMID 12851308.
5. Brzoska T et al. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in experimental medicine and biology. 2010. PMID 21222263.
6. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177.
7. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases. 2008. PMID 18092346.
8. Land SC et al. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International journal of physiology, pathophysiology and pharmacology. 2012. PMID 22837805.
9. Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and molecular gastroenterology and hepatology. 2016. PMID 27458604.
10. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters. 1988. PMID 3169264.
11. Pickart L et al. The human tri-peptide GHK and tissue remodeling. Journal of biomaterials science. Polymer edition. 2008. PMID 18644225.
12. Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed research international. 2015. PMID 26236730.
13. Sikiric P et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current neuropharmacology. 2016. PMID 27138887.
14. Seiwerth S et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current pharmaceutical design. 2018. PMID 29998800.
15. Xiao B et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy. 2017. PMID 28143741.
16. Songok AC et al. Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue. PloS one. 2018. PMID 29953505.
17. Luger TA et al. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the rheumatic diseases. 2007. PMID 17934097.
18. Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine reviews. 2008. PMID 18612139.
19. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery. 2026. PMID 42542926.
20. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis. 2012. PMID 22962027.
21. Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024. PMID 38382158.
22. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany). 2017. PMID 27847966.

Research use: Apex materials are supplied for laboratory research, not human or veterinary consumption. This guide explains identity, research and documentary evidence; it does not provide administration or treatment instructions.